Results 51 to 60 of about 242,580 (385)

Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. [PDF]

, 2013
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with no effective treatment to date. Despite its multi-factorial aetiology, oxidative stress is hypothesized to be one of the key pathogenic mechanisms.
Azzouz, M, Higginbottom, A, Nanou, A, Ning, K, Shaw, P, Valori, CF, Wyles, M   +6 more
core   +1 more source

The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Frontiers in Neuroscience, 2020
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has been made to unravel the genetics of these disorders, and, based on this work, it is now clear ...
Yevgeniya A. Abramzon, P. Fratta, B. Traynor, Ruth Chia   +3 more
semanticscholar   +1 more source

Conjugal Amyotrophic Lateral Sclerosis [PDF]

Baylor University Medical Center Proceedings, 2012
Amyotrophic lateral sclerosis (ALS) is a disease characterized by progressive degeneration of motor neurons in the motor cortex, brainstem, and spinal cord. The incidence of sporadic ALS is 1.5 to 2.7 in 100,000, and the prevalence is 5.2 to 6.0 in 100,000. Conjugal ALS is even rarer than sporadic ALS.
John D, Dewitt, Julia, Kwon, Rebecca, Burton, Jeffrey S, Stroup   +3 more
openaire   +2 more sources

Promoting Independence Through Effective Interventions For Adults With ALS [PDF]

, 2020
PICO Question What are effective occupational therapy interventions for adults with ALS to improve participation in ADLs/IADLs? Objectives Define amyotrophic lateral sclerosis (ALS) and recognize the prevalence Identify and describe evidence-based ...
Gluchowski, OTS, Renee, Harris, OTS, Hannah, Heineman, OTS, Jaclyn, Kendro, OTS, Kimberly, Malosky, OTS, Heather   +4 more
core   +1 more source

Letter to the editor: autoimmune pathogenic mechanisms in amyotrophic lateral sclerosis [PDF]

, 2018
The innate immune system may affect the function and survival of motor neurons in ALS by at least three mechanisms. First, there is evidence to suggest that aggregates of mutant SOD1—which is derived from microglial and astroglial cells—activate ...
de Vincentiis, M., De Virgilio, A., Gallo, A., Greco, A., Inghilleri, M., Ralli, M.   +5 more
core   +1 more source

Progressive brainstem pathology in motor neuron diseases: Imaging data from amyotrophic lateral sclerosis and primary lateral sclerosis

Data in Brief, 2020
A standardised, single-centre, longitudinal imaging protocol was used to evaluate longitudinal brainstem alterations in 100 patients with amyotrophic lateral sclerosis (ALS) with reference to 33 patients with primary lateral sclerosis (PLS), 30 patients ...
Peter Bede, Rangariroyashe H. Chipika, Eoin Finegan, Stacey Li Hi Shing, Kai Ming Chang, Mark A. Doherty, Jennifer C. Hengeveld, Alice Vajda, Siobhan Hutchinson, Colette Donaghy, Russell L. McLaughlin, Orla Hardiman   +11 more
doaj   +1 more source

Cervical spinal cord atrophy in amyotrophic lateral sclerosis across disease stages

Annals of Clinical and Translational Neurology, 2023
Objective Spinal cord degeneration is a hallmark of amyotrophic lateral sclerosis. The assessment of gray matter and white matter cervical spinal cord atrophy across clinical stages defined using the King's staging system could advance the understanding ...
Anna Nigri, Eleonora Dalla Bella, Stefania Ferraro, Jean Paul Medina Carrion, Greta Demichelis, Enrica Bersano, Monica Consonni, Antje Bischof, Mario Stanziano, Sara Palermo, Giuseppe Lauria, Maria Grazia Bruzzone, Nico Papinutto   +12 more
doaj   +1 more source

Improving clinical trial outcomes in amyotrophic lateral sclerosis

Nature Reviews Neurology, 2020
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s — a lack of effective therapies.
M. Kiernan, S. Vucic, K. Talbot, C. Mcdermott, O. Hardiman, J. Shefner, A. Al-Chalabi, W. Huynh, M. Cudkowicz, P. Talman, L. H. van den Berg, T. Dharmadasa, P. Wicks, C. Reilly, M. Turner   +14 more
semanticscholar   +1 more source

Amyotrophic Lateral Sclerosis.

Internal Medicine, 1995
The final cascade of amyotrophic lateral sclerosis (ALS) coincides with the onset of clinical neurological deficits and involves multifactorial interactive mechanisms. These terminal events include excitotoxicity, free radical accumulation and possibly immunological disturbances.
openaire   +2 more sources

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source